Effective cancer therapy through immunomodulation.

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31

Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76

Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res (2012) 1.37

Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci U S A (2007) 1.26

Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res (2010) 1.18

Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am J Pathol (2009) 1.06

Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res (2016) 0.96

Systematic review of randomized controlled trials of pharmacological interventions to reduce ischaemia-reperfusion injury in elective liver resection with vascular occlusion. HPB (Oxford) (2010) 0.93

Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol (2011) 0.91

TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. Cancer Immunol Immunother (2009) 0.91

Specific and randomly derived immunoactive peptide mimotopes of mycobacterial antigens. Clin Vaccine Immunol (2006) 0.90

Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology (2013) 0.85

Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. J Immunol (2010) 0.84

Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood (2014) 0.82

Orthosiphon stamineus protects Caenorhabditis elegans against Staphylococcus aureus infection through immunomodulation. Biol Open (2014) 0.82

Cytokine treatment of macrophage suppression of T cell activation. Immunobiology (2009) 0.79

Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors. J Immunother (2008) 0.78

The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol (2011) 0.78

Genome-wide DNA methylation profiling and its involved molecular pathways from one individual with thyroid malignant/benign tumor and hyperplasia: A case report. Medicine (Baltimore) (2016) 0.77

CD28 ligation increases macrophage suppression of T-cell proliferation. Cell Mol Immunol (2012) 0.76

Curcumin up regulates T helper 1 cells in patients with colon cancer. Am J Transl Res (2017) 0.75

Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma. Cancer Biother Radiopharm (2009) 0.75

Potential of targeting TGF-β for organ transplant patients. Future Med Chem (2013) 0.75